148148-48-5

Basic information

• Product Name: BENZYL 4-(N-METHOXY-N-METHYLCARBAMOYL)PIPERIDINE-1-CARBOXYLATE
• Synonyms: BENZYL 4-(N-METHOXY-N-METHYLCARBAMOYL)PIPERIDINE-1-CARBOXYLATE;1-CBZ-4-(METHOXY-METHYL-CARBAMOYL)-PIPERIDINE;4-(METHOXY-METHYL-CARBAMOYL)-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER;1-Cbz-N-Methoxy-N-Methyl-4-piperidinecarboxaMide
• CAS NO: 148148-48-5
• Molecular Formula: C₁₆H₂₂N₂O₄
• Molecular Weight: 306.36
• Mol File: 148148-48-5.mol

Chemical Properties

• Boiling Point: 422.1±55.0 °C(Predicted)
• Appearance: /
• Density: 1.191±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -2.36±0.40(Predicted)
• CAS DataBase Reference: BENZYL 4-(N-METHOXY-N-METHYLCARBAMOYL)PIPERIDINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: BENZYL 4-(N-METHOXY-N-METHYLCARBAMOYL)PIPERIDINE-1-CARBOXYLATE(148148-48-5)
• EPA Substance Registry System: BENZYL 4-(N-METHOXY-N-METHYLCARBAMOYL)PIPERIDINE-1-CARBOXYLATE(148148-48-5)

Safety Data

• Hazardous Substances Data: 148148-48-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
BENZYL 4-(N-METHOXY-N-METHYLCARBAMOYL)PIPERIDINE-1-CARBOXYLATE is used as a key intermediate in the synthesis of new drugs and pharmaceuticals. Its unique structure and properties make it a promising candidate for the development of innovative therapeutic agents.
Used in Organic Chemistry:
In the field of organic chemistry, BENZYL 4-(N-METHOXY-N-METHYLCARBAMOYL)PIPERIDINE-1-CARBOXYLATE serves as a versatile building block for creating new chemical compounds with a variety of applications. Its reactivity and functional groups allow for further chemical modifications and the formation of complex organic molecules.
Used in Drug Development:
BENZYL 4-(N-METHOXY-N-METHYLCARBAMOYL)PIPERIDINE-1-CARBOXYLATE is utilized in drug development as a potential active pharmaceutical ingredient (API). Its specific structure may contribute to the discovery of new therapeutic agents with novel mechanisms of action and improved pharmacological properties.
Used in Synthesis of Organic Molecules:
In the synthesis of organic molecules, BENZYL 4-(N-METHOXY-N-METHYLCARBAMOYL)PIPERIDINE-1-CARBOXYLATE acts as a valuable precursor, enabling the creation of a wide range of chemical compounds with diverse applications in various industries, including materials science, agrochemicals, and specialty chemicals.

Upstream product

• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 10314-98-4 1-benzyloxycarbonylpiperidine-4-carboxylic acid 
• 1068-55-9 isopropylmagnesium chloride 
• 160809-38-1 1-benzyl 4-ethyl piperidine-1,4-dicarboxylate 
• 501-53-1 benzyl chloroformate 
• 498-94-2 isonipecotic acid 
• 1117-97-1 N,0-dimethylhydroxylamine 
• 10314-99-5 benzyl 4-(chlorocarbonyl)piperidine-1-carboxylate 

Downstream Products

• 160809-34-7 4-acetyl-piperidine-1-carboxylic acid benzyl ester 
• 138163-08-3 N-(benzyloxycarbonyl)piperidine-4-carboxaldehyde 
• 184289-85-8 benzyl spiro[indole-3,4'-piperidine]-1'-carboxylate 
• 455267-29-5 4-(1-amino-ethyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 816464-47-8 benzyl 4-(2-bromoacetyl)piperidine-1-carboxylate 
• 816464-50-3 benzyl 4-({3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-2-yl}carbonyl)piperidine-1-carboxylate 
• 816464-48-9 benzyl 4-[(3-amino-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-2-yl)carbonyl]piperidine-1-carboxylate 
• 816464-49-0 benzyl 4-[(3-bromo-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-2-yl)carbonyl]piperidine-1-carboxylate 
• 816464-65-0 3-[(2,4-difluorophenyl)amino]-7-phenyl-2-(piperidin-4-ylcarbonyl)-thieno[2,3-b]pyridin-6(7H)-one 
• 1186238-94-7 1-(1-(4-chlorophenyl)piperidin-4-yl)-2-nitrobutan-1-ol 

Relevant articles and documents

A pharmaceutical intermediate of PROTAC molecules targeting monoacylglycerol lipase. Preparation method and application

The invention discloses a medical intermediate of PROTAC molecules targeting monoacylglycerol lipase, a preparation method and an application thereof, and relates to the field of medicines. It has the structure shown I: formula I. The hydroxyl end has the

Ugi-type reactions of spirocyclic indolenines as a platform for compound library generation

A simple and efficient method for the synthesis of highly substituted spiroindoline derivatives is presented. A Fischer indolization is combined with Ugi-type reactions to explore the chemical space concerning this privileged structure. Moreover, spiropip

Renin Inhibitors

Disclosed are compounds having the formula (I): wherein the R1, R2, R3, X, Y, A, L, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.

HYDROXYALKANYL AMIDES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The application describes modulators of MIP-1α or CCR-1 of the formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein ring A, T, V, R1, R2 and R5, are defined herein. In addition, me

RENIN INHIBITORS

Disclosed are compounds of Formula (I) wherein the R, R1, R2, R3, X, Y, A, Q, E, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.

Novel substituted (pyridin-3-yl)phenyloxazolidinones: Antibacterial agents with reduced activity against monoamine oxidase A and increased solubility

Oxazolidinones represent a new and promising class of antibacterial agents. Current research in this area is mainly concentrated on improving the safety profile and the antibacterial spectrum. Oxazolidinones bearing a (pyridin-3-yl)phenyl moiety (e.g., 3) generally show improved antibacterial activity compared to linezolid but suffer from potent monoamine oxidase A (MAO-A) inhibition and low solubility. We now disclose the finding that new analogues of 3 with acyclic substituents on the pyridyl moiety exhibit excellent activity against Gram-positive pathogens, including linezolid-resistant Streptococcus pneumoniae. Generally, more bulky substituents yielded significantly reduced MAO-A inhibition relative to the unsubstituted compound 3. The MAO-A SAR can be rationalized on the basis of docking studies using a MAO-A/MAO-B homology model. Solubility was enhanced with incorporation of polar groups. One optimized analogue, compound 13, showed low clearance in the rat and efficacy against S. pneumoniae in a mouse pneumonia model.

3- `4- {6-SUBSTITUTED ALKANOYL) PYRIDIN-3-YL} -3-PHENYL! -5- (1H-1, 2, 3-TRIAZOL-1-YLMETHYL) -1, 3-OXAZOLIDIN-2-ONES AS ANTIBACTERIAL AGENTS

Compounds of formula (I) as well as pharmaceutically-acceptable salts and pro-drugs thereof are disclosed wherein R1, R2, R3, and R4 are defined herein. Also disclosed are processes for making compounds of formula (I) as well as methods of using compounds of formula (I) for treating bacterial infections.

SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present invention relates to compounds having the general formula [I] or a pharmaceutically acceptable salt thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititi

THIENOPYRIDONE DERIVATIVES AS KINASE INHIBITORS

A series of thieno[2,3-b]pyridin-6(7H)-one derivatives, substituted in the 2-position by a carbonyl- or sulfonyl-linked pyrrolidin-3-yl, pyrrolidin-3-ylamino or related moiety, being inhibitors of p38 MAP kinase, are accordingly of use in medicine, for ex

SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present invention relates to compounds having the general formula (I) or a pharmaceutically acceptable salt thereof, wherein Rl is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, wherein the ring may be fused with a benzo group, and is substituted by 0, 1 or 2 oxo groups, and wherein R1 is additionally substituted; and R2 is a substituted C1-6balkyl. Also included is a method of prophylaxis or treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.